IL-8 Inhibitor
CAS No. 138559-60-1
IL-8 Inhibitor ( ——— )
产品货号. M41330 CAS No. 138559-60-1
Antileukinate 是一种六肽,是有效的 CXC 趋化因子受体 (CXCR) 抑制剂。Antileukinate 能抑制中性粒细胞趋化和活化。Antileukinate 可用于急性炎症和损伤的研究。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 25MG | 获取报价 | 有现货 |
|
| 50MG | 获取报价 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
生物学信息
-
产品名称IL-8 Inhibitor
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Antileukinate 是一种六肽,是有效的 CXC 趋化因子受体 (CXCR) 抑制剂。Antileukinate 能抑制中性粒细胞趋化和活化。Antileukinate 可用于急性炎症和损伤的研究。
-
产品描述Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury.
-
体外实验Antileukinate (52.63 mg/kg; s.c.) protectes mice against acute pancreatitis and associated lung injury.Antileukinate (5mg/kg; s.c.) inhibits the interaction between murine eotaxin and murine eosinophil.Animal Model:Swiss mice (20-25g)Dosage:52.63 mg/kg Administration:Subcutaneous injectionResult:Reduced pancreatic edema induced by Caerulein (50 μg/kg).
-
体内实验Antileukinate inhibits the binding of human eotaxin to human eosinophils with an IC50 of 8.2 μM.Antileukinate (10-100 μM; 2 hours) significantly suppresses eosinophil chemotaxis to human eotaxin.
-
同义词———
-
通路Others
-
靶点Other Targets
-
受体———
-
研究领域———
-
适应症———
化学信息
-
CAS Number138559-60-1
-
分子量1003.2
-
分子式C45H66N18O7S
-
纯度>98% (HPLC)
-
溶解度———
-
SMILES———
-
化学全称———
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Madhav Bhatia, et al. Treatment with antileukinate, a CXCR2 chemokine receptor antagonist, protects mice against acute pancreatitis and associated lung injury. Regul Pept. 2007 Jan 10;138(1):40-8.?
产品手册
关联产品
-
PUMA BH3 (TFA)
PUMA BH3 (TFA) is a p53 upregulated modulator of apoptosis (PUMA) BH3 domain peptide, acts as a direct activator of Bak, with a Kd of 26 nM.
-
Mepivacaine
甲哌卡因。
-
3-Feruloyl-4-caffeoy...
3-阿魏酰-4-咖啡酰奎尼酸是绿原酸异构体。绿原酸是相关的咖啡品质标志、味道和香气前体以及重要的生物活性化合物。
021-51111890
购物车()
sales@molnova.cn

